The PSA Screening for HIM Act amends section 2713 of the Public Health Service Act to require group health plans and health insurance issuers offering group or individual coverage to provide and exempt from cost-sharing additional evidence-based prostate cancer preventive services for men age 40 and older who are at high risk of prostate cancer (explicitly including African‑American men and men with a defined family history). The bill also adds a statutory definition for “men with a family history of prostate cancer” that includes relatives with diagnoses, deaths from prostate cancer, cancers associated with increased risk, or known genetic alterations.
Why it matters: the bill takes a targeted, risk-based approach to preventive coverage and would push private payers to absorb the cost of PSA-related screening for a defined high‑risk population starting with plan years beginning January 1, 2026. That changes payer obligations, creates practical implementation questions about how risk is verified and coded, and inserts a statutory exception related to certain USPSTF breast-cancer guidance that could complicate preventive coverage interpretation.
At a Glance
What It Does
The bill inserts a new subparagraph into PHSA section 2713(a) requiring plans and issuers to cover — without cost‑sharing — additional evidence‑based prostate cancer preventive services for men 40+ at high risk. It leaves existing USPSTF A/B coverage requirements intact and adds a rule letting plans cover services beyond USPSTF recommendations.
Who It Affects
Applies to group health plans and health insurance issuers offering group or individual coverage (including employer‑sponsored and individual market policies administrated under PHSA section 2713). It primarily affects men age 40+ who meet the bill’s high‑risk definition, primary care and urology providers, clinical laboratories, and plan administrators who must change coverage rules and claims processing.
Why It Matters
The measure creates a targeted preventive‑coverage entitlement for a population identified in congressional findings as having elevated risk, potentially lowering financial barriers and changing utilization patterns. It also raises operational and evidentiary questions for regulators and payers about who qualifies as ‘high‑risk’, what counts as an ‘evidence‑based’ prostate screening, and how to reconcile the bill’s USPSTF-related language with existing guidance.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill modifies the federal preventive‑coverage rule that currently requires plans to cover services that receive an “A” or “B” from the U.S. Preventive Services Task Force without cost‑sharing. It keeps that baseline intact and adds a new, specific requirement for prostate cancer: plans must provide and cannot impose cost‑sharing for additional evidence‑based prostate cancer preventive services aimed at men age 40 and older who are at high risk of prostate cancer.
The high‑risk reference explicitly calls out African‑American men and men with a family history.
To operationalize the family‑history trigger, the bill defines “men with a family history of prostate cancer” by listing qualifying circumstances: a first‑degree relative diagnosed with or who died from prostate cancer; a relative diagnosed with a cancer known to raise prostate‑cancer risk; or a relative with a genetic alteration associated with increased prostate cancer risk. The statute therefore ties coverage to a mixture of clinical, familial, and genetic indicators rather than to a single lab or age cut‑off alone.The measure also contains two technical clauses that matter in practice.
First, it includes a “rule of construction” that explicitly allows plans to cover services beyond USPSTF recommendations. Second, it inserts a narrowly worded clarification on breast cancer screening that treats the USPSTF’s “current recommendations” as the operative standard while excluding recommendations issued “in or around November 2009,” language that could create interpretive disputes over which historical USPSTF guidance applies.Implementation will require insurers and employers to update benefits and claims systems to exempt the specified prostate‑screening services from copays, coinsurance, and deductibles for qualifying men.
The bill sets an effective date tied to plan years beginning on or after January 1, 2026, which gives payers a single upcoming plan‑year window to adjust formularies, preauthorization rules, coding, and member communications. The statute does not itself define which prostate screening tests qualify, nor does it direct a federal agency to issue an immediate technical standard; those operational details are left to regulators and payers to resolve.
The Five Things You Need to Know
The bill amends PHSA §2713(a) to add a new subparagraph requiring no cost‑sharing for additional evidence‑based prostate cancer preventive services for men age 40+ who are at high risk of prostate cancer.
It defines “men with a family history of prostate cancer” by listing five qualifying circumstances (first‑degree relative diagnosed with prostate cancer, developed prostate cancer, death from prostate cancer, a relative diagnosed with a cancer associated with increased prostate‑cancer risk, or a relative with a genetic alteration linked to increased risk).
The statute contains a rule of construction permitting plans to provide preventive services beyond USPSTF recommendations rather than limiting coverage only to USPSTF A/B items.
The bill includes a specific clarification that treats the USPSTF’s current breast‑cancer screening, mammography, and prevention recommendations as operative except for those issued “in or around November 2009,” an unusual carve‑out that may require regulatory interpretation.
The amendment’s effective date is calibrated to plan years beginning on or after January 1, 2026, meaning payers must implement coverage changes for the 2026 plan year cycle.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Names the statute the “Prostate‑Specific Antigen Screening for High‑risk Insured Men Act” (PSA Screening for HIM Act). This is purely titular but signals Congress’s intent to focus coverage changes narrowly on PSA‑related preventive services for a high‑risk male population.
Findings
Lists epidemiological and disparity‑focused findings (incidence, mortality, racial disparities, family history risk, and cost differences between metastatic and localized disease). While non‑binding, these findings frame legislative intent and will be cited by agencies and courts when interpreting ambiguous phrases such as “high risk” or “evidence‑based.”
Adds targeted no‑cost coverage for high‑risk men
Inserts a new subparagraph (E) into the list of no‑cost preventive services. Subparagraph (E) requires plans and issuers to cover “additional evidence‑based preventive care and screenings” for prostate cancer for men age 40+ who are at high risk, and it explicitly identifies African‑American men and men with a family history as examples of the high‑risk group. Practically, this places PSA‑related preventive services into the same no‑cost umbrella that applies to USPSTF A/B services for a defined subset of enrollees.
Statutory definition of family history
Creates a multi‑part definition of “men with a family history of prostate cancer” tied to a first‑degree relative and enumerating diagnosis, development of disease, death from prostate cancer, related cancers, or a known genetic alteration. The breadth of the definition means plans cannot limit eligibility to narrow pedigree formulas; however, the statute does not specify documentation standards (medical record, genetic test, attestation), leaving those operational choices to plans and regulators.
USPSTF and rule‑of‑construction language; effective date
The bill adds a clause treating current USPSTF breast‑cancer recommendations as operative while excluding recommendations issued around November 2009 and inserts a rule that nothing in the subsection prevents plans from covering services beyond USPSTF guidance. Finally, the effective date applies the amendment to plan years beginning on or after January 1, 2026. The combination of the carve‑out and rule‑of‑construction will matter for how HHS and courts resolve conflicts between statutory language and evolving USPSTF guidance.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- High‑risk men (African‑American men and those with qualifying family history): the statute eliminates cost‑sharing for covered prostate preventive services, which lowers financial barriers to screening and could increase early detection for this explicitly targeted group.
- Primary care and urology practices: increased screening uptake typically results in higher visit volume, PSA testing, and downstream diagnostic procedures, shifting more preventive and diagnostic work to outpatient clinicians.
- Clinical laboratories and diagnostic imaging providers: covering PSA‑related screening without cost‑sharing is likely to increase test volume and associated laboratory revenue, and may increase demand for follow‑up imaging or biopsies.
- Health equity organizations and community health programs: the bill’s targeting of known disparity groups creates a statutory lever to argue for outreach and funding to raise screening rates in underserved populations.
Who Bears the Cost
- Group health plans and health insurance issuers (including employer‑sponsored plans and individual market carriers): plans must waive copays/coinsurance/deductibles for the covered services for qualifying members, increasing near‑term claims costs and administrative change work.
- Self‑insured employers and third‑party administrators: ERISA‑governed self‑insured employers that qualify as group health plans will need to update plan documents, benefits communications, and claims processing systems to implement the no‑cost requirement.
- Insurers and marketplaces potentially passing costs to premiums: plans facing higher utilization or more follow‑up care may repricing risk pools, potentially affecting premiums and employer contributions.
- Federal and state regulators and plan administrators: HHS, DOL, and state insurance regulators will need to issue guidance on acceptable documentation of “family history,” what tests count as covered preventive services, and how to reconcile the USPSTF carve‑out, increasing regulatory workload.
Key Issues
The Core Tension
The bill forces a trade‑off between two legitimate objectives: reducing financial barriers to screening for men at higher risk (aiming to address racial and familial disparities and improve early detection) versus preserving an evidence‑based preventive framework intended to limit overdiagnosis and overtreatment; expanding mandated coverage for a targeted group increases utilization but may also expand low‑value care unless regulators and payers define strict clinical thresholds.
The bill creates an operational and evidentiary gap. It requires coverage for “additional evidence‑based” prostate preventive services for a defined high‑risk group but does not specify which tests, intervals, or clinical criteria qualify as ‘‘evidence‑based’’ in this context.
The USPSTF remains the statutory touchstone for A/B preventive services, but the bill’s new subparagraph (E) points to services “not described in subparagraph (A)” and does not direct a federal agency to produce implementing technical guidance. That leaves payers and agencies to decide whether PSA testing, baseline testing ages, repeat intervals, and adjunctive tests (free PSA, mpMRI, genetic panels) qualify for the no‑cost rule.
The bill also inserts an unusual line about USPSTF breast‑cancer recommendations — excluding those “issued in or around November 2009” — a drafting feature that is likely to generate interpretive disputes. Regulators will have to decide which historical recommendations are excluded, and whether that clause was intended to freeze or reject a specific past USPSTF position.
Finally, the statute imposes a risk‑based entitlement designed to reduce disparities, but it risks increasing overdiagnosis and low‑value downstream interventions. Payers must balance short‑term screening costs and potential increases in biopsies and treatments against the long‑term value of reducing late‑stage disease; absent implementation guidance, clinicians and plans may adopt heterogeneous thresholds for who qualifies as high‑risk, undermining uniform access.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.